Coronary Endothelial Dysfunction Is Associated With Elevated Serum PCSK9 Levels in People With HIV Independent of Low-Density Lipoprotein Cholesterol
Overview
Authors
Affiliations
Background HIV + people are at increased risk of coronary artery disease, but the responsible mechanisms are incompletely understood. Proprotein convertase subtilisin/kexin type 9 ( PCSK 9) is traditionally recognized for its importance in cholesterol metabolism; however, recent data suggest an additional, low-density lipoprotein receptor-independent adverse effect on endothelial cell inflammation and function. We tested the hypotheses that PCSK 9 levels are increased and that abnormal coronary endothelial function is related to PCSK 9 serum levels in HIV + individuals. Methods and Results Forty-eight HIV + participants receiving antiretroviral therapy with suppressed viral replication, without coronary artery disease, and 15 age- and low-density lipoprotein cholesterol-matched healthy HIV- subjects underwent magnetic resonance imaging to measure coronary endothelial function, quantified as percentage change in coronary artery cross-sectional area during isometric handgrip exercise, an endothelial-dependent stressor; and blood was obtained for serum PCSK 9 and systemic vascular biomarkers. Data are presented as mean±SD. Mean serum PCSK 9 was 65% higher in the HIV + subjects (302±146 ng/ mL ) than in the HIV - controls (183±52 ng/ mL , P<0.0001). Coronary endothelial function was significantly reduced in the HIV + versus HIV - subjects (percentage change in coronary artery cross-sectional area, 2.9±9.6% versus 11.1±3.7%; P<0.0001) and inversely related to PCSK 9 ( R=-0.51, P<0.0001). Markers of endothelial activation and injury, P-selectin and thrombomodulin, were also significantly increased in the HIV + subjects; and P-selectin was directly correlated with serum PCSK 9 ( R=0.31, P=0.0144). Conclusions Serum PCSK 9 levels are increased in treated HIV + individuals and are associated with abnormal coronary endothelial function, an established measure of vascular health.
Lipoprotein(a) and Cardiovascular Disease in People Living With HIV: The Next Horizon.
Hanna D, Rodriguez C J Am Heart Assoc. 2024; 13(23):e039074.
PMID: 39609261 PMC: 11681576. DOI: 10.1161/JAHA.124.039074.
Kikuchi D, Kwapong Y, Schar M, Weiss R, Sun K, Brown T J Am Heart Assoc. 2024; 13(23):e035975.
PMID: 39575706 PMC: 11681595. DOI: 10.1161/JAHA.124.035975.
Transgender Women with HIV Demonstrate Unique Non-Alcoholic Fatty Liver Disease Profiles.
Lake J, Hyatt A, Feng H, Miao H, Somasunderam A, Utay N Transgend Health. 2024; 9(5):413-420.
PMID: 39449788 PMC: 11496901. DOI: 10.1089/trgh.2022.0182.
Ronn C, Knudsen A, Arentoft N, Thudium R, Heidari S, Sivapalan P Front Med (Lausanne). 2024; 11:1337609.
PMID: 39114826 PMC: 11304346. DOI: 10.3389/fmed.2024.1337609.
PCSK9 Inhibitor: Safe Alternative to Fill the Treatment Gap in Statin-Limited Conditions?.
Xiao Y, Ba Z, Pang S, Liu D, Wang H, Liang H Rev Cardiovasc Med. 2024; 23(11):380.
PMID: 39076187 PMC: 11269069. DOI: 10.31083/j.rcm2311380.